Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.
The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.
For more information, please visit www.harbourbiomed.com
Company Details
- Employees
- 107
- Address
- 1 Broadway,
- Phone
- +86-21-51370990
- co****@****med.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- harbourbiomed.com
- HQ
- Cambridge, Massachusetts
Harbour Biomed Questions
Harbour Biomed's helpline number is +86-21-51370990
Harbour Biomed's website is harbourbiomed.com
Harbour Biomed's LinkedIn profile is https://www.linkedin.com/company/harbour-biomed
Harbour Biomed has
107 employees.
View email and phone details for 107
employees at Harbour Biomed.
Harbour Biomed's industry is
Biotechnology Research
Harbour Biomed's top competitors are
Caribou Biosciences,
Karyopharm Therapeutics Inc.,
Innovent Biologics,
Beigene,
Hifibio Therapeutics,
Zai Lab,
Insilico Medicine,
Parabilis Medicines,
Nona Biosciences,
Biocytogen.
Harbour Biomed's support email address is contact@harbourbiomed.com
Harbour Biomed's categories are Biotechnology Research
